Citations

Clear

154 citation(s) found for "Levin, G".

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age
Voorhees, Peter M. , Cohen, Yaël C. , Lindsay, Jindriska, Suzuki, Kenshi , Beksaç, Meral , Magen, Hila , Garate, Gonzalo, Theunissen, Koen, Mylin, Anne K., Hallam, Simon , Bringhen, Sara, Uttervall, Katarina , Ye, J Christine, Cowan, Andrew J. , Mateos, María‐Victoria , Goldschmidt, Hartmut , Vieyra, Diego, Raval, Ashta, Sha, Linlin, Rousseau, Els, Dennis, Robyn M., Carson, Robin, Dimopoulos, Meletios Α. , Schjesvold, Fredrik , Hungria, Vânia , Sandhu, Irwindeep , Baker, Ross , Kosugi, Hiroshi , Levin, Mark-David , Stockerl‐Goldstein, Keith , Oriol, Albert , Mikala, Gábor , Špıčka, Ivan , Bringhen, Sara, Puła, Bartosz , Khan, Abdullah , Medvedova, Eva , Moreau, Philippe, Raval, Ashta, Li, Liang , Carson, Robin, Rajkumar, S. Vincent

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 372-372

10.1182/blood-2025-372 Get It

Abstract Introduction : Current standard of care for smoldering multiple myeloma (SMM), an asymptomatic precursor of multiple myeloma (MM), is observation until progression to active MM. Increasing evidence suggests that patients (pts) with SMM at high risk for progression to active MM may benefit from early treatment (tx). In AQUILA, a phase 3 study in pts with high-risk SMM (NCT03301220), daratumumab (Dara) monotherapy significantly reduced risk of progression to active MM or death with a trend of extending overall survival (OS) vs active monitoring (ActMon), with no new safety concerns. Given the evolution in SMM risk stratification, a post hoc analysis was performed to assess outcomes using the IMWG 2020 and IMWG 2020 plus cytogenetic risk models to assess which AQUILA pts benefited most from Dara monotherapy. Safety and efficacy analysis by age and stem cell collection outcomes were also assessed. Methods: Eligible pts with a confirmed diagnosis (≤5 y) of high-risk SMM per IMWG 2014 criteria, defined as clonal bone marrow plasma cells (BMPC) ≥10% and ≥1 risk factor (IgA SMM, serum protein ≥30 g/dL, serum involved:uninvolved free light chain [I/U FLC] ratio ≥8 and <100, immunoparesis with reduction of 2 uninvolved Ig isotypes, and/or clonal BMPC >50% to <60%) at study entry, were randomized 1:1 to receive subcutaneous Dara or ActMon for 39 cycles, 36 months, or until confirmed disease progression (PD), whichever came first. Primary endpoint was progression-free survival (PFS) assessed by independent review committee, defined as progression to active MM (based on IMWG SLiM-CRAB diagnostic criteria) or death. Secondary endpoints included time to first-line (1L) MM tx and OS. For this post hoc analysis, we assessed outcomes by age, IMWG 2020 high-risk SMM criteria (BMPC >20%, monoclonal spike >2 g/dL, serum FLC ratio >20; ≥2 factors=high risk; also known as the Mayo 2018 or the 20-2-20 criteria), and the IMWG 2020 plus cytogenetic criteria (IMWG 2020 criteria + presence of ≥1 high-risk cytogenetic abnormalities [t(4;14), t(14;16), +1q and/or del13q]; ≥3 factors=high risk). Results : Dara tx showed a PFS benefit across all IMWG 2020 risk subgroups (low: hazard ratio [HR], 0.59; intermediate: HR, 0.70), with the largest benefit in the high-risk subgroup, where the PD/death rate in the ActMon arm was ~1.6-fold that in the Dara arm (62.8% vs 37.5%; HR, 0.36). This benefit of Dara vs ActMon was preserved over time, with 5-year PFS rates of 78.2% vs 71.6%, 56.2% vs 42.9%, and 60.4% vs 23.6% in IMWG 2020 low-, intermediate-, and high-risk groups, respectively. There was a positive trend favoring Dara for time to 1L MM treatment across all IMWG 2020 risk groups (low-risk HR, 0.63; 95% CI, 0.22–1.80; intermediate-risk HR, 0.57; 95% CI, 0.35–0.92; high-risk HR, 0.39; 95% CI, 0.25–0.62). IMWG 2020 plus cytogenetic risk classification results will be available at the time of presentation. When comparing the younger (<65y HR, 0.51; 95% CI, 0.32–0.79) vs the older (≥65y, HR, 0.50; 95% CI, 0.32–0.77) pt population, a PFS benefit was observed regardless of age. Similarity was also observed in TEAE incidence rate when looking into <65, 65 to <75, and ≥75 y subgroups (82.7%, 81.1%, and 87.5% with ActMon; 96.2%, 98.5%, and 95.2% with Dara); however, serious TEAEs were more frequently observed in older ActMon pts (12.2%, 18.9%, and 50.0% with ActMon; 24.8%, 35.8%, and 28.6% with Dara). Across all pts treated/monitored in AQUILA, 23 (11.9%) and 41 (20.9%) pts in the Dara and ActMon arms, respectively, received autologous stem cell transplant as part of their first tx after progressing to active MM, with very limited plerixafor use (Dara, 3 [1.6%] vs ActMon, 9 [4.6%]). Median (range) CD34+ cell yield was 5.0 (2–20)×106 cells/kg body weight among 22 pts in the Dara arm and 5.1 (2–21)×106 cells/kg body weight among 39 pts in the ActMon arm. Conclusions : In this analysis, pts with high-risk SMM from the phase 3 AQUILA study treated with Dara monotherapy experienced long-term PFS benefit across IMWG 2020 subgroups, with the most pronounced benefit in the high-risk subgroup. No notable differences in PFS or safety were observed across age subgroups. Early Dara tx for high-risk SMM did not have a detrimental impact on stem cell yield. Although mature OS analyses are forthcoming, overall, these results further support early intervention with Dara monotherapy vs ActMon among pts with high-risk SMM, regardless of risk stratification criteria used.
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Colman, Howard , Lombardi, Giuseppe , Wong, Eric T. , Walbert, Tobias , Lassman, Andrew B. , Peereboom, David M. , Kizilbash, Sani H. , Matsuoka, Carlos Kamiya , Pitz, Marshall , Desjardins, Annick , Kumthekar, Priya , Mason, Warren , Pellerino, Alessia , Butowski, Nicholas , Hamza, Mohamed A. , Lallana, Enrico C., Uhlmann, Erik J. , Welsh, Liam , Wen, Patrick Y. , Dietrich, Jörg , Wang, Chao , Levin, Victor A. , Lassman, Andrew B , Peereboom, David M , Kizilbash, Sani H , Kamiya-Matsuoka, Carlos , Pitz, Marshall W , Strowd, Roy E , Desjardins, Annick , Kumthekar, Priya , Mason, Warren , Pellerino, Alessia , Soffietti, Riccardo , Butowski, Nicholas A , Forsyth, Peter A , Hamza, Mohamed A , Hau, Peter , Nabors, Louis Burt , Uhlmann, Erik J , Welsh, Liam C , Wen, Patrick Yung , Dietrich, Jorg , Wang, Chao , Levin, Victor A , Colman, Howard , Eoli, Marica , Strowd, Roy E. , Soffietti, Riccardo , Hau, Peter , Nabors, Burt , Piccioni, David Eric , Lombardi, G

Mayo Clinic

Journal of Clinical Oncology | December 1, 2025 | Volume: 44 | Issue: 8 | Pages: 641-652

10.1200/jco-25-01204 | PMID 41325560 Get It

PURPOSE STELLAR (ClinicalTrials.gov identifier: NCT02796261 ) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. METHODS At trial initiation, eligibility criteria included: age ≥18 years, anaplastic astrocytoma (2016 WHO CNS Tumor classification [WHO CNS4]), first recurrence ≥6 months after radiation and temozolomide (TMZ), Karnofsky performance status ≥70, and no imaging findings consistent with grade 4 glioblastoma. Random assignment (1:1) was stratified by isocitrate dehydrogenase ( IDH ) mutation, age, resection extent, and geography. Patients received eflornithine (2.8 g/m 2 orally, every 8 hours [2 weeks on, 1 week off]) + lomustine (90 mg/m 2 orally, once every 6 weeks), or lomustine monotherapy (110 mg/m 2 once every 6 weeks). The primary end point was overall survival (OS). RESULTS Among 343 patients randomly assigned across 74 sites in eight countries, there was no difference in survival between eflornithine + lomustine and lomustine monotherapy (median OS 23.4 v 20.3 months, hazard ratio [HR], 0.94). Following changes in classification and grading in the 2021 WHO CNS5, a subset analysis of patients with IDH- mutant, grade 3 astrocytoma (n = 196), defined in 2024, before unblinding, showed clinically meaningful improvements in median OS with eflornithine + lomustine versus lomustine monotherapy (34.9 v 23.5 months, HR, 0.64) and median progression-free survival (PFS, 15.8 v 7.2 months, HR, 0.57). No differences were observed among patients with CNS grade 4 disease. Grade ≥3 treatment-emergent adverse events of relevance were related to reversible myelosuppression (eflornithine + lomustine 42% v lomustine monotherapy 29% of patients) and hearing impairment (24% v 0%). No new safety signals were identified. CONCLUSION Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH -mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action.
Introducing a foundational sequence transformer for range adaptive nucleotide decoding (STRAND)
Ayanian, Shant , Osborne, Collin , Xu, Clark , Molnar, Carl, Das, Pravat, Perez, Xoab, Vassilieva, Natalia , Pondenkandath, Vinay, Kanakiya, Bhargav, Venkatesh, Ganesh, Redlon, Matt , Shah, Vijay H. , Callstrom, Matthew R. , Korfiatis, Panos, Ryu, Alexander J. , Blasi, Marc, Callstrom, Matthew, Ryu, Alexander J. , Myasoedova, Elena , Molnar, Carl, Das, Pravat, Levin, May, Blasi, Marc, Lazaridis, Konstantinos N. , Myasoedova, Elena , Xu, Clark

Mayo Clinic

Briefings in Bioinformatics | November 24, 2025 | Volume: 26 | Issue: 6 | Pages: No page available

10.1093/bib/bbaf618 | PMID 41283814 Get It

Abstract The advent of high-throughput sequencing has led to an exponential increase in genomic data, highlighting the need for efficient and accurate models to analyze and interpret this information. In this study, we introduce a novel, exomic foundational model that leverages a combination of the human reference genome and multispecies data to improve variant detection and interpretation. Our model utilizes a short-range transformer architecture and is trained on a large dataset of human exomic sequences derived from the Tapestry study. Through a series of ablation studies and scaling experiments, we demonstrate the effectiveness of our model in predicting next token accuracy and identifying clinically pathogenic variants. We also show that our model outperforms existing models in a range of downstream tasks, including variant effect prediction and disease state identification. In fact, our largest sequence transformer for range adaptive nucleotide decoding variant (1B parameters) surpassed previous benchmarks, demonstrating a mean accuracy of 0.880 [an 8.2% improvement over the original nucleotide transformer (NT) and a 7% improvement over NT-v2]. Furthermore, we construct a unique exomic ClinVar dataset to evaluate the model’s performance on pathogenicity and disease states. Our results highlight the potential of this model to improve our understanding of the human exome and its role in disease. The model and its applications have significant implications for genomics-based diagnosis and personalized medicine, including tailored therapeutic development.
CTNI-58. UPDATED RESULTS OF PHASE 3 STELLAR TRIAL: EFLORNITHINE IMPROVES OVERALL SURVIVAL AND BLINDED INDEPENDENT CENTRAL REVIEW DETERMINED PROGRESSION FREE SURVIVAL IN PATIENTS WITH RECURRENT WHO 2021 GRADE 3 IDH-MUTANT ASTROCYTOMA
Colman, Howard , Walbert, Tobias , Lassman, Andrew B. , Kizilbash, Sani H. , Kamiya-Matsuoka, Carlos, Pitz, Marshall , Desjardins, Annick , Kumthekar, Priya , Mason, Warren, Butowski, Nicholas , Forsyth, Peter, Hamza, Mohamed A. , Lallana, Enrico C., Uhlmann, Erik J. , Welsh, Liam , Wen, Patrick Y. , Dietrich, Jörg , Levin, Victor A. , Kizilbash, Sani H , Colman, Howard , Lombardi, Giuseppe , Wong, Eric T. , Eoli, Marica , Peereboom, David M. , Strowd, Roy E. , Pellerino, Alessia , Soffietti, Riccardo , Hau, Peter , Nabors, Burt , Piccioni, David Eric , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v139-v140

10.1093/neuonc/noaf201.0554 Get It

Abstract BACKGROUND STELLAR was a phase III randomized, open-label trial of eflornithine (ornithine decarboxylase inhibitor) with lomustine versus lomustine alone in patients with recurrent anaplastic astrocytoma (AA). We previously reported an overall survival (OS) and progression free survival (PFS) of the combination in the patients with grade 3 IDH-mutant astrocytoma. Here we report updated OS and PFS outcomes based on additional molecular classification and blinded independent central review (BICR). METHOD Eligibility included: age ≥ 18 years, AA (2016 WHO criteria) with first recurrence ≥ 6 months after radiation, KPS ≥ 70, and no imaging findings consistent with grade 4 glioblastoma. Patients received eflornithine (2.8 g/m2 TID Q 2/3 weeks) with lomustine (90 mg/m2 Q 6 weeks) (Arm A) or lomustine alone (110 mg/m2 Q 6 weeks) (Arm B). Primary endpoint was OS. RESULTS Updated molecular data resulted in re-classification of the 343 AA patients enrolled into 3 WHO 2021 defined tumor subtypes, 196 tumors were IDHmut, CDKN2A/B intact, consistent with diagnosis of astrocytoma, IDHmut, WHO grade 3, 33 tumors had CDKN2A/B loss consistent with astrocytoma, IDHmut, WHO grade 4, 106 tumors were IDHwt consistent with diagnosis of glioblastoma, IDHwt, WHO grade 4. Updated results strengthen initial conclusion that eflornithine plus lomustine resulted in significant survival benefit in the astrocytoma, IDHmut, WHO grade 3 group (mOS 34.9 vs, 23.5 months, HR = 0.64, stratified log rank p =0.0136). PFS with eflornithine was also improved (15.8 vs, 7.2 months, HR = 0.57, stratified log rank p =0.0113). BICR demonstrated a high correlation between investigator and centrally determined PFS (p=0.0305), and high correlation between OS and PFS (p=.0001). CONCLUSION The clinically meaningful OS and PFS benefits observed with eflornithine in the molecularly defined 2021 WHO CNS grade 3 astrocytomas is further confirmed and expanded based on additional molecular classification and BICR of PFS.
Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
Srinivas, Sandy, Ahmed, Bilawal , An, Yi , Bitting, Rhonda L. , Chapin, Brian F. , D’Amico, Anthony V. , Desai, Neil , Dorff, Tanya B. , Eastham, James A., Farrington, Thomas A., Gao, Xin , Gupta, Shilpa , Karnes, R. Jeffrey, Kishan, Amar U. , Kuettel, Michael, Lee, Daniel , Morgan, Todd M. , Pessoa, Rodrigo Rodrigues , Roach, Mack , Rosenfeld, Stan, Scarpato, Kristen R., Shabsigh, Ahmad , Valicenti, Richard K., Wong, J.K. , Kovách, E, Freedman-Cass, Deborah A., Morgan, Todd M , Robin, Tyler P. , Spratt, Daniel E. , Adra, Nabil , Cheng, Heather H. , Cho, Steve Y. , Ippolito, Joseph E. , Lang, Joshua M. , Lotan, Tamara Levin , McDonald, Andrew, Rais‐Bahrami, Soroush , Szmulewitz, Russell Z , Teply, Benjamin A. , Tward, Jonathan D. , VanderWeele, David James , Kovach, Emily

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 10, 2025 | Volume: 23 | Issue: 11 | Pages: 469-493

10.6004/jnccn.2025.0052 | PMID 41213253 Get It

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum. The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). For patients with mCSPC, disease characteristics, such as whether metastases arose synchronously or metachronously and the degree of metastatic burden, impact therapy decisions, including how much treatment intensification is appropriate and when prostate-directed and/or metastasis-directed therapy should be considered. In the mCRPC setting, androgen deprivation therapy is continued with the sequential or concurrent addition of certain androgen receptor pathway inhibitors, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, biomarkers, the extent and location of metastases, symptoms, and potential side effects.
Early treatment in migraine – A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society
Pozo‐Rosich, Patricia , Caronna, Edoardo , Sacco, Simona , Peres, Mário Fernando Prieto , Ashina, Sait , Özge, Aynur , Velez-Jimenez, Maria Karina, Jenkins, Bronwyn , Sakai, Fumihiko , Levin, Morris , Tassorelli, Cristina , Rozen, Todd D. , Wang, Shuu-Jiun , Schwedt, Todd J , Burstein, Rami , Terwindt, Gisela , Tassorelli, Cristina , Pozo-Rosich, Patricia , Ashina, Sait , Sacco, Simona , Ozge, Aynur , Ahmed, Fayyaz , Vélez-Jiménez, María-Karina , Wang, Shuu‐Jiun , Schwedt, Todd J. , Burstein, Rami , Terwindt, Gisela M.

Mayo Clinic

Cephalalgia | October 24, 2025 | Volume: 45 | Issue: 10 | Pages: No page available

10.1177/03331024251387721 | PMID 41134822 Get It

Migraine is one of the most disabling diseases worldwide, especially when it transforms into chronic migraine, which is often associated with medication overuse and can become resistant or even refractory to treatments. Molecular, neuroimaging and neurophysiological changes have been described in chronic migraine, some of which might not be fully reversible with preventive treatment. For these reasons, we should aim to prevent this transition, and initiate preventive treatment before disease becomes refractory and burden increases. Preventive migraine treatments are often delayed because of access to care, stigma leading to undertreatment and patients’ reluctance as a result of fear of side effects and, in some cases, fear of being labeled as chronically ill. With the availability of effective and well-tolerated preventive treatments, we must shift our mindset and take advantage of new opportunities to initiate preventive treatment earlier. In this International Headache Society position statement, we propose a migraine preventive strategy under the idea of shifting from reactive treatment once disability is established (prevention of attacks), to proactive, individualized prevention initiated early with safe, effective and tolerable therapies (prevention of disease progression). This approach is based on 1) promoting the early initiation of effective and tolerable preventive therapies, starting from two to four monthly migraine days in line with the majority of current guidelines and recommendations and 2) fostering longitudinal studies to gather more evidence on the potential benefit of early prevention, with the final goal of improving patient outcomes, promoting excellent migraine care, enhancing individual and social well-being, and, ultimately, preventing migraine progression and preserving brain health.
Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab
Wechsler, Michael E., Agmon‐Levin, Nancy , Jayne, David , Specks, Ulrich , Sjö, Lena Börjesson, Necander, Sofia , Shavit, Anat , Walton, Claire, Merkel, Peter A. , Jayne, David , Specks, Ulrich , Merkel, Peter A , Wechsler, Michael E , Pagnoux, Christian

Mayo Clinic

ACR Open Rheumatology | August 31, 2025 | Volume: 7 | Issue: 9 | Pages: No page available

10.1002/acr2.70096 | PMID 40886121 Get It

ObjectiveIn the phase 3 head‐to‐head MANDARA study (NCT04157348), benralizumab demonstrated noninferiority to mepolizumab in inducing remission (defined as Birmingham Vasculitis Activity Score [BVAS] of 0 and oral glucocorticoid [OGC] dosage ≤4 mg/day at weeks 36 and 48) in patients with eosinophilic granulomatosis with polyangiitis (EGPA). This analysis investigated a more stringent definition of remission that included discontinuation of OGCs and being relapse‐free.MethodsPatients aged ≥18 years with documented relapsing or refractory EGPA receiving OGCs at ≥7.5 mg/day with or without immunosuppressive therapy for ≥4 weeks before enrollment were randomized (1:1) to benralizumab at 30 mg or mepolizumab at 300 mg subcutaneously every 4 weeks for 52 weeks. The proportion of patients achieving remission off OGCs, defined as BVAS of 0, OGC dose of 0 mg/day (at weeks 36 and 48) and no relapses during the double‐masked period, was assessed.ResultsPatients (n = 140) were randomized to benralizumab (n = 70) or mepolizumab (n = 70). The adjusted percentage of patients with remission off OGCs was 23.5% (n = 16) with benralizumab versus 11.1% (n = 8) with mepolizumab (difference 12.47 [95% confidence interval 0.46–24.48], P = 0.042). Of those who achieved remission off OGCs, 100% of benralizumab‐treated patients and 98.6% of mepolizumab‐treated patients achieved remission within the first 36 weeks of treatment.ConclusionThe administration of anti–interleukin‐5/receptor (IL‐5/R) therapies, benralizumab and mepolizumab, enable discontinuation of OGCs in some patients with EGPA, while avoiding relapses. These findings suggest that adding anti‐IL‐5/R therapy to standard primary treatment for patients with EGPA may improve response.
Recent-onset atrial fibrillation: challenges and opportunities
Svennberg, Emma , Andrade, Jason G. , Anselmino, Matteo , Biton, Yitschak , Brandes, Axel , Buckley, Claire , Espuny, Josep Lluis Clua , Doehner, Wolfram , Domínguez, Helena , Fauchier, Laurent , Glotzer, Taya V. , Hendriks, Jeroen , Hills, Mellanie True , Hindricks, Gerhard , Joung, Boyoung , Levin, Lars‐Åke , Liu, Shaowen , Lobban, Trudie , Macfarlane, Peter W. , Mairesse, Georges H. , Marcus, Gregory M. , Orchard, J. , Reiffel, James A. , Siontis, Konstantinos C. , Stavrakis, Stavros , Svendsen, Jesper Hastrup , Teh, A. , Tieleman, Robert G , Camm, A. John , Freedman, Ben , Andrade, Jason G , Anselmino, Matteo , Biton, Yitschak , Boriani, Giuseppe , Brandes, Axel , Buckley, Claire , Cameron, Alan C , Lluis Clua Espuny, Josep , Crijns, Harry J G M , Diederichsen, Søren Z , Doehner, Wolfram , Dominguez, Helena , Duncker, David , Fauchier, Laurent , Glotzer, Taya , Guo, Yutao , Haeusler, Karl G , Haim, Moti , Healey, Jeffrey S , Hendriks, Jeroen M , True Hills, Mellanie , Hindricks, Gerhard , Hobbs, F D Richard , Johnson, Linda S B , Joung, Boyoung , Kamel, Hooman , Kirchhof, Paulus , Lane, Deirdre A , Levin, Lars-Åke , Lip, Gregory Y H , Liu, Shaowen , Lobban, Trudie , Macfarlane, Peter W , Mairesse, Georges , Marcus, Gregory M , Noseworthy, Peter A , Ntaios, George , Orchard, Jessica J , Passman, Rod , Reidpath, Daniel D , Reiffel, James A , Ribeiro, Antonio Luiz , Rivard, Lena , Sanders, Prashanthan , Sandhu, Roopinder K , Schnabel, Renate B , Siontis, Konstantinos C , Sposato, Luciano A , Stavrakis, Stavros , Steinhubl, Steven , Svendsen, Jesper Hastrup , Teh, Andrew W , Themistoclakis, Sakis , Tieleman, Robert G , Camm, Alan John , Freedman, Ben , Boriani, Giuseppe , Cameron, Alan C. , Crijns, Harry J.G.M. , Diederichsen, Søren Zöga , Duncker, David , Haim, Moti , Healey, Jeff S. , Hobbs, Richard , Johnson, Linda S.B. , Kamel, Hooman , Kirchhof, Paulus , Lane, Deirdre A. , Noseworthy, Peter A. , Passman, Rod , Rivard, Léna , Sanders, Prashanthan , Schnabel, Renate B. , Sposato, Luciano A. , Tieleman, RG

Mayo Clinic

European Heart Journal | June 23, 2025 | Volume: 47 | Issue: 2 | Pages: 170-187

10.1093/eurheartj/ehaf478 | PMID 40873195 Get It

Abstract Atrial fibrillation (AF) is increasingly diagnosed early, close to its first occurrence due to: (i) increased public awareness with self-screening; (ii) health care initiatives including population screening and opportunistic case finding; and (iii) increased use and surveillance of implantable cardiac devices. At its onset, AF is often low burden, and cardiovascular co-morbidities may be absent or at an early stage. Thus, the management of recent-onset AF has become an issue of growing importance. Professional guidelines have traditionally focused on anticoagulant thromboprophylaxis, generally recommending a cautious approach to rhythm control, and priority has been given to rate control to alleviate symptoms. In recent guidelines, the importance of managing lifestyle and co-morbidities has increased. The AF-SCREEN collaboration proposes that a vigorous approach to active management of recent-onset AF may be warranted. This includes addressing co-morbidities and promoting healthy lifestyles to prevent the emergence or progression of AF and associated cardiovascular disease, as well as the initiation of active rhythm control ± anticoagulation to prevent AF-related morbidity and mortality, including stroke and heart failure (HF). Intuitively, intervention early after AF onset would be beneficial since lifestyle and co-morbidity management, plus rhythm control and anticoagulation, are important contributors to improved outcomes in patients with established AF, but robust evidence is lacking for recent-onset AF. There is a delicate balance between achieving favourable outcomes such as preventing strokes, HF and AF progression vs the complications and potential adverse effects of interventions. Given the serious long-term consequences, innovative approaches are necessary to determine the value and risks of initiating active therapy very early in the course of AF. More data are needed to guide the best management of recent-onset AF, bearing AF burden in mind. Long-term studies using large national databases linked to electronic medical records and rhythm monitoring devices offer excellent opportunities. Shorter-term studies focusing on reducing AF burden to slow AF progression and studies focusing on outcomes such as HF could be used in both randomized clinical trials and observational cohort studies.
Practice patterns and experiences of pediatric rehabilitation medicine physicians in cancer rehabilitation
Tsao, Elaine , Levin, Jared, Gober, Joslyn , Chaviano, Kelli , Tsetlina, Vera , Javaid, Simra , Tsao, Elaine Ya-Wei , Lynch, Mary Elizabeth, Lynch, Mary Elizabeth

Mayo Clinic

PM&R | May 24, 2025 | Volume: 17 | Issue: 11 | Pages: 1334-1342

10.1002/pmrj.13395 | PMID 40411370 Get It

Abstract Background Pediatric cancer rehabilitation is a growing field, and pediatric rehabilitation medicine physicians play an important role in the care continuum for children and adolescents with cancer. However, the current practice patterns and experiences of pediatric physiatrists in cancer rehabilitation are not well known. Objective To evaluate the status of pediatric cancer rehabilitation care by board‐certified pediatric physiatrists in the United States, including their practice pattern, experience, and comfort level in cancer‐related conditions. Design An online 37‐question Research Electronic Data Capture survey was developed by members of a pediatric cancer rehabilitation committee of a national physiatry organization. Descriptive data analysis was performed. Setting Survey invitations were sent via email to potential participants and posted on social media sites, including an online physiatry community forum and a pediatric physiatrist private group. Patients (or Participants) Targeted participants were board‐certified pediatric physiatrists who treat pediatric patients with cancer diagnoses. Interventions Not applicable. Main Outcome Measure(s) Survey questions pertained to respondents' practice setting and patient population, type of cancer rehabilitation provided, presence of a cancer rehabilitation program at their institution, and their learning experience in pediatric cancer rehabilitation. Results A total of 107 board‐certified pediatric physiatrists completed the survey, representing 57 institutions in the United States, the majority of which were academic centers ( n = 95; 88.8%). Ninety‐seven (90.7%) reported their practice consisted of >75% pediatric patients, and 95 (88.8%) indicated <25% pediatric patients in the practice have cancer diagnoses. Forty respondents representing 19 institutions (33.3%) reported an established cancer rehabilitation program at their institution, though of these, 23 (57.5%) indicated that more improvement to their program was needed. Sixty‐three respondents (58.9%) gained experience in cancer rehabilitation from fellowship, 51 (47.7%) from residency, and 47 (43.9%) from mentorship; majority ( n = 102; 95.3%) also learned from self‐study or on the job. Participants' comfort level on cancer‐related conditions varied. Conclusions This survey, aimed at board‐certified pediatric physiatrists who practice pediatric cancer rehabilitation, highlights the variety in training experiences and practice exposure among respondents. Concomitant with this was a variance in reported comfort levels in treating the different cancer‐related diagnoses. This raises for discussion what training opportunities might be strengthened as the subspeciality continues to grow.